AI assistant
Pulmonx Corp — Director's Dealing 2021
Jun 22, 2021
34428_dirs_2021-06-21_97b89152-e47f-4646-8609-db91be7f7e28.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Pulmonx Corp (LUNG)
CIK: 0001127537
Period of Report: 2021-06-17
Reporting Person: French Glendon E. III (Director, President and CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-06-17 | Common Stock | M | 4375 | $2.20 | Acquired | 1252359 | Direct |
| 2021-06-17 | Common Stock | S | 20071 | $42.83 | Disposed | 1232288 | Direct |
| 2021-06-17 | Common Stock | S | 4929 | $43.47 | Disposed | 1227359 | Direct |
| 2021-06-17 | Common Stock | S | 1000 | $42.68 | Disposed | 25571 | Indirect |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-06-17 | Employee Stock Option (right to buy) | $2.20 | M | 4375 | Disposed | 2030-08-27 | Common Stock (4375) | Direct |
Footnotes
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2020.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.27 to $43.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.27 to $43.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Glendon E. French III Children's Irrevocable Trust on December 15, 2020.
F5: The shares are directly held by the Glendon E. French III Children's Irrevocable Trust dated 11-17-98 for which the Reporting Person is a trustee.
F6: The shares subject to the option are immediately exercisable and vest in 48 equal monthly installments beginning on August 28, 2020, subject to the Reporting Person's continuous service through each such vesting date.